IRIDEX (IRIX) Expected to Announce Quarterly Earnings on Thursday

IRIDEX (NASDAQ:IRIX) will likely be releasing its Q4 2025 results after the market closes on Thursday, March 26th. Analysts expect IRIDEX to post earnings of ($0.02) per share and revenue of $14.74 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 5:00 PM ET.

IRIDEX Stock Performance

NASDAQ:IRIX opened at $1.35 on Wednesday. The company has a current ratio of 1.94, a quick ratio of 1.35 and a debt-to-equity ratio of 62.29. The company has a market capitalization of $23.21 million, a P/E ratio of -4.50 and a beta of 0.67. The firm has a 50-day moving average price of $1.41 and a two-hundred day moving average price of $1.20. IRIDEX has a twelve month low of $0.79 and a twelve month high of $1.65.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC lifted its stake in shares of IRIDEX by 93.9% during the 4th quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 15,377 shares during the period. Apexium Financial LP grew its position in shares of IRIDEX by 53.0% in the third quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock valued at $116,000 after purchasing an additional 34,834 shares during the period. Susquehanna International Group LLP increased its stake in IRIDEX by 46.2% in the third quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 17,834 shares during the last quarter. Finally, Citadel Advisors LLC increased its stake in IRIDEX by 62.7% in the third quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock valued at $126,000 after purchasing an additional 42,202 shares during the last quarter. 20.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. iA Financial set a $3.00 price target on shares of IRIDEX in a research report on Thursday, February 5th. Alliance Global Partners initiated coverage on IRIDEX in a research report on Thursday, February 5th. They set a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IRIDEX in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, IRIDEX currently has an average rating of “Hold” and a consensus price target of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.